Diana Mckenzie - May 1, 2025 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
May 1, 2025
Transactions value $
$0
Form type
4
Date filed
5/5/2025, 04:52 PM
Previous filing
Apr 3, 2025
Next filing
May 30, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MCKENZIE DIANA Director C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON /s/ Christiana Stevenson, Attorney-in-Fact 2025-05-05 0001754648

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +796 +32.68% $0.00 3.23K May 1, 2025 Direct F1
transaction VRTX Common Stock Disposed to Issuer -1K -30.97% 2.23K May 1, 2025 Direct F2
holding VRTX Common Stock 207 May 1, 2025 Held in Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Deferred Stock Units Award +1K +16.71% 6.99K May 1, 2025 Common Stock 1K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
F2 Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2024, Ms. McKenzie deferred the receipt of 1,001 shares of common stock and received instead 1,001 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,001 shares of common stock in exchange for an equal number of deferred stock units.
F3 Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.